<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001041.v1.p1" parentStudy="phs001041.v1.p1" createDate="2015-12-14" modDate="2016-05-20">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Timothy Chan, MD, PhD, Vice Chair, Department of Radiation Oncology</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Financial Support</td><td>Frederick Adler Fund, Timothy Chan</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Swim across America</td><td>Jedd Wolchok, MD, PhD</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Ludwig Trust</td><td>Jedd Wolchok, MD, PhD</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Melanoma Research Alliance</td><td>Jedd Wolchok, MD, PhD</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma</StudyNameEntrez>
	<StudyNameReportPage>Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Longitudinal Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells.</p> <p>We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens generated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients.</p> <p>Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P = 0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neo-antigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti-CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion: patients with melanoma who were treated with ipilimumab or tremelimumab</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="25409260"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Melanoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Timothy Chan, MD, PhD, Vice Chair, Department of Radiation Oncology</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Financial Support">
			<AttName>Frederick Adler Fund, Timothy Chan</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Swim across America">
			<AttName>Jedd Wolchok, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Ludwig Trust">
			<AttName>Jedd Wolchok, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Melanoma Research Alliance">
			<AttName>Jedd Wolchok, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Stand Up to Cancer-Cancer Research Institute Immunotherapy Dream Team">
			<AttName>Jedd Wolchok, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Stand Up to Cancer-Cancer Research Institute Immunotherapy Dream Team">
			<AttName>Timothy Chan, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="STARR Cancer Consortium">
			<AttName>Jedd Wolchok, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="STARR Cancer Consortium">
			<AttName>Timothy Chan, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="National Institutes of Health">
			<AttName>Timothy Chan, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Ruth L. Kirschstein National Research Service Award (T32CA009512)">
			<AttName>Alexandra Snyder, MD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-PUB-NPU-MDS" longName="Health/Medical/Biomedical (PUB, NPU, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001041.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001041.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001041.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical (PUB, NPU, MDS)</ConsentName>
        <ConsentAbbrev>HMB-PUB-NPU-MDS</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor agrees to make results of studies using the data available to the larger scientific community.
Use of the data is limited to not-for-profit organizations.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
